SMS Pharmaceuticals Ltd. Q2 FY26 Financial Results & Corporate Update

Key Financial Highlights (Q2 FY26 vs. Q2 FY25) Net Profit: The company's consolidated net profit recorded substantial growth, rising 76.4% YoY to ₹25.14 crore, compared to ₹14.25 crore in the corresponding period last year. This bottom-line expansion is a strong indicator of enhanced profitability. Revenue from Operations: Top-line growth was solid, with revenue increasing 23.2% YoY to ₹242.4 crore from ₹196.7 crore. This performance was underpinned by healthy and sustained demand across the company's key product segments. EBITDA & Margin Expansion: Operational excellence was a key driver for the quarter. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) grew by 51.8% YoY to ₹48.34 crore. Crucially, the EBITDA margin saw a significant expansion of 375 basis points, improving to 19.94% from 16.19% in the prior-year period. This margin accretion reflects successful cost efficiency measures and an improved product mix. Strategic & Capital Utilization Update In a separate regulatory update, the company confirmed its disciplined approach to capital allocation. Fund Utilization: Management affirmed that there has been no deviation or variation in the utilization of funds raised through its preferential issue. Strategic Deployment: The capital, raised following the conversion of 90 lakh warrants (completed in tranches in March 2025 and September 2025), is being strategically deployed as planned. Growth Initiatives: These funds are being channeled into critical growth areas, including capacity expansion, backward integration of key starting materials (KSMs), and augmenting working capital to support the scaling operations. Market Summary The company's stock has registered a year-to-date gain of approximately 13% (as of November 7, 2025). This quarter's strong results demonstrate successful strategy execution and reinforce the company's position for sustainable growth.